After successful pancreas transplantation, recipients with type I diabetes mellitus achieve a return to normal fasting plasma glucose levels, normal oral glucose tolerance tests, and normal levels of HbA,C (1-7). However, whether recipients undergo alterations in counterregulatory hormonal responses to glycopenia, or improvement in counterregulation of hypoglycemia, has not been determined. These are important considerations because type I diabetic patients commonly have defective glucagon and epinephrine responses to hypoglycemia and, consequently, deranged counterregulation of hypoglycemia with its attendant risks (8-13). Therefore, presence or absence of improvement in these responses are highly relevant factors in the evaluation of the overall benefits of pancreas transplantation. Moreover, since the transplanted pancreas is denervated and since islet alpha cell and pancreatic polypeptide cell function is neurally modulated, investigation of pancreas recipients offers a unique opportunity to assess regulation ofglucagon and pancreatic polypeptide secretion from the pancreas in humans in the setting of absent central nervous system input into the islet.
After successful pancreas transplantation, recipients with type I diabetes mellitus achieve a return to normal fasting plasma glucose levels, normal oral glucose tolerance tests, and normal levels of HbA,C (1-7). However, whether recipients undergo alterations in counterregulatory hormonal responses to glycopenia, or improvement in counterregulation of hypoglycemia, has not been determined. These are important considerations because type I diabetic patients commonly have defective glucagon and epinephrine responses to hypoglycemia and, consequently, deranged counterregulation of hypoglycemia with its attendant risks (8) (9) (10) (11) (12) (13) . Therefore, presence or absence of improvement in these responses are highly relevant factors in the evaluation of the overall benefits of pancreas transplantation. Moreover, since the transplanted pancreas is denervated and since islet alpha cell and pancreatic polypeptide cell function is neurally modulated, investigation of pancreas recipients offers a unique opportunity to assess regulation ofglucagon and pancreatic polypeptide secretion from the pancreas in humans in the setting of absent central nervous system input into the islet.
To evaluate hormonal counterregulation of hypoglycemia in patients with type I diabetes mellitus who have received successful pancreas allografts, we have examined glucose, glucagon, pancreatic polypeptide, and catecholamine responses during insulin-induced hypoglycemia. We have also assessed glucagon and pancreatic polypeptide responsivity to direct stimulators of alpha and pancreatic polypeptide cells (arginine and secretin, respectively) to ascertain whether possible alterations in secretory responses in pancreas recipients are specific for hypoglycemic signaling or more general in nature. In this study, the responses of pancreas recipients were compared with responses of patients with similar durations of type I diabetes mellitus, who had not received pancreas transplantation, and to nondiabetic control subjects.
Methods
Subjects. 38 type I diabetic recipients of pancreas allografts with iliac vessel anastomoses and with intact native pancreases who had been transplanted between 3 and 60 mo previously were studied (Table I) . All recipients were normoglycemic, had normal hemoglobin A,C levels and mildly elevated serum creatinine levels, and none were receiving exogenous insulin or other medication for diabetes. Immunosuppression was achieved with the triple-drug regimen of azathioprine, cyclosporine, and prednisone (14) . 54 patients with type I diabetes and with similar age, sex distribution, body-mass index, serum creatinine levels, and duration ofdiabetes, as well as 26 normal volunteers of similar age, sex distribution, and body-mass index, were studied to obtain control data. All subjects were admitted to the University . Catecholamines were measured using a radioenzymatic method described previously (17) .
Data analysis. Data are expressed as mean±SEM unless otherwise stated. Statistics for intergroup compansons were performed by analysis of variance followed by Fisher's least significant difference. When applicable, Student's paired or unpaired t test were used. Discrete variables were compared by chi-squares analysis. Least-squares linear regression was used to assess bivariate interdependency. All P values were for two-tailed distributions and P < 0.05 was considered statistically significant.
Results
Glucose suppression and recovery during insulin tolerance testing. Similar blood glucose nadirs were obtained in all three groups (1.8±0.1 mM in recipients, 2.0±0.1 mM in nonrecipients, and 2.0±0.1 mM in controls; P = NS). However, the fall in glucose tended to be somewhat slower in the nonrecipients than in the two other groups (Fig. 1 ). Blood glucose recovery after insulin-induced hypoglycemia in diabetic nonrecipients was severely impaired, the maximal blood glucose recovery being only 8±2% of decrement. Blood glucose recovery was significantly better in recipients (34±4% of decrement; P < 0.0001) but significantly lower than that observed in controls (58±3% of decrement; P < 0.0001). All normal subjects and diabetic patients reached glucose levels below 2.6 mM and all completed at least 35 min of this test from the time of insulin injection. Only 2 of 24 recipients could not complete the test because of symptoms ofhypoglycemia. In contrast, the test was prematurely terminated by giving intravenous glucose because of marked symptoms of hypoglycemia in 19 out of 48 nonrecipients (P < 0.01). Consequently, the mean data illustrated in Figs. 1, 5, and 6 most likely result in an overestimation of blood glucose recovery and of hormonal responses during the last third of the test in the nonrecipient group because only those nonrecipients with comparatively less impaired hormonal responses were able to complete the test. In a subset of 12 type I diabetic patients who were studied before and after pancreas transplantation, blood glucose recovery after insulin-induced hypoglycemia improved in each individual and the difference in blood glucose recovery was highly significant (13±6% vs. 42±6% of decrement; P < 0.0001; Fig. 2) .
Glucagon responses to insulin-induced hypoglycemia and to stimulation with arginine. Basal glucagon levels at normoglycemia were higher in recipients (192±23 ng/liter) than in nonrecipients (115±9 ng/liter; P < 0.001) and controls (1 13±12 ng/liter; P < 0.01; Fig. 1 ). During insulin-induced hypoglycemia very little increase in glucagon levels was observed in the nonrecipients. In contrast, glucagon levels increased significantly during hypoglycemia in recipients and in normal control subjects. Maximal incremental glucagon responses to hypoglycemia (Amax) in recipients (170±31 ng/ liter) were significantly greater (P < 0.0001) than nonrecipients (37±7 ng/liter, P < 0.0001), and similar to that observed in controls (125±15 ng/liter). In the subset of 12 type I diabetics studied before and after pancreas transplantation, maximal incremental glucagon responses were significantly improved (52±15 vs. 225±57 ng/liter; P < 0.02). Blood glucose recovery correlated significantly with incremental glucagon responses when all recipient data were used (r = 0.49, n = 24, P < 0.0001), but in the subset of 12 recipients this correlation was not significant (r = 0.38, n = 12). The effect of beta adrenergic blockade on glucagon secretion during hypoglycemia in three pancreas recipients was examined to ascertain whether improved glucagon responses were related to beta adrenergic input. Glucagon responses were unaffected by an intravenous infusion of propranolol (80 ,ug/min) given before and during hypoglycemia (Fig. 3) . Glucagon responses to arginine were also determined in recipients, nonrecipients, and normal control subjects to compare alpha cell responsiveness with direct stimulation. Basal glucagon values were approximately two-fold elevated in recipients compared with nonrecipients and controls (Fig. 4) , Glucose and glucagon data obtained at 60 min after the injection of insulin in 12 type I diabetic recipients who were tested before and after pancreas transplantation. Glucose data are expressed as a percentage of the absolute fall in glucose levels (pretest levels minus nadir levels), and glucagon levels are expressed as peak increments over pretest glucagon values. These 12 type I diabetic recipients were tested before and after pancreas transplantation. Differences in plasma glucose recovery at 60 min are significant at P < 0.0001, and differences in maximal glucagon increments are significant at P < 0.02.
and integrated incremental glucagon responses under the curve were significantly greater in recipients (1910±207) compared with nonrecipients (710±70; P < 0.0001) and with controls (1 109±162 ng/liter X min, P < 0.001). Catecholamine responses to insulin-induced hypoglycemia. Epinephrine responses to insulin-induced hypoglycemia were highly variable in all three groups (Fig. 5) , with a trend towards impaired responses in nonrecipients. However, no significant differences in basal levels or in peak incremental epinephrine responses were observed among nonrecipients (2.2±0.3), recipients (2.3±0.4), and controls (2.6±0.4 nmol/liter). The results obtained from 6 type I diabetics studied before and after pancreas transplantation also showed no improvement in peak .ie for eahsuecircpins6±4n=and nonrecipients, and when comparing prospectively the e for each suject) inrecipients(67±24; n ' glucose responses in the subset of recipients we studied before ents (45+19. n = 25), and normal control subjects and after pancreas transplantation. A marked increase in basal mol/liter; n = 17) did not differ. and stimulated glucagon secretion was associated with the improved glucose recovery after hypoglycemia in the pancreas oion recipients. In this subset, 4 of the 12 recipients had no imes described herein were designed to determine the provement in glucagon responses but two had improved episuccessful pancreas transplantation in type I diabetic nephnne responses (in the other two epinephnne data were not obtained), which may explain the improvement in glucose recovery. The reason for the elevated basal glucagon levels is uncertain. Systemic venous drainage of the allograft may be an important factor since glucagon secreted by the allograft would INSULIN reach the systemic circulation before and not after metabolism by the liver. The liver is known to be an important site of glucagon metabolism with normal hepatic glucagon extraction estimated at 20-25% (18, 19 control subjects (open circles). There were no significant during stimulation with arginine. Our data also suggest that among the three groups.
islet alpha cells in humans do not require central nervous system inputs to respond to glycopenia, although it is generally accepted that central nervous system inputs into the endocrine pancreas participate in islet alpha cell responses to hypoglycemia. The contention that our patients' allografts remained denervated at the time of study seems reasonable since many of our patients were studied by 3 mo after pancreas transplantation. Moreover, even if reinnervation was to occur, it is extremely unlikely that this would establish the normal neural mechanisms inherent in the native pancreas because our patients allografts were positioned in an heterotopic position in the pelvis rather than in the area surrounding the normal pancreatic bed. An alternative interpretation of our data is that return to normoglycemia for an extended period of time may have improved alpha cell function so that hypoglycemia could stimulate secretion from the native pancreas. There are not a great deal of reported data to argue against this possibility, although it has been reported that patients treated with insulin pumps and achieving normoglycemia for a period of up to 12 mo still had defective glucagon responses to hypoglycemia (21, 22) . Although there are very few studies of this nature and glucose control with intensive insulin treatment is not as fine as one can obtain through pancreas transplantation, we think it is worth considering that the marked improvement in glucagon secretion in pancreas recipients could be due to the allograft exclusively, since it is well appreciated that alpha cells respond to hypoglycemia in the absence of sympathetic or parasympathetic innervation.
In our study, no significant differences were observed in pancreatic polypeptide responses or catecholamine responses during insulin-induced hypoglycemia when comparing recipients and nonrecipients of pancreas allografts. Interestingly, glucagon responses to arginine, which are not neurally mediated, were greater in the recipients compared with nonrecipients, whereas no significant differences between these two groups were observed in pancreatic polypeptide responses to secretin, which require vagal innervation of the islet (23, 24) . This further suggests that the transplanted allografts in our patients remained denervated up to the time of our studies. That pancreatic polypeptide secretion is quantitatively similar in recipients and nonrecipients suggests that secretion of this hormone in both groups occurs from native pancreas only. If this reasoning is correct, serial monitoring of pancreatic polypeptide responses may provide a valuable metabolic marker for possible future allograft reinnervation should it occur. Although there appeared to be a trend towards improvement in the epinephrine responses in pancreas recipients, there were no significant differences in the epinephrine responses among the three groups. Regardless, because of this trend and because of the possibility of denervation hypersensitivity to adrenergic stimulation, we wished to establish whether the improved glucagon responses in the recipients might be related to increased adenergic input into pancreatic islet alpha cells through betaadenergic stimulation (25) . That propranolol failed to diminish the glucagon responses to hypoglycemia reinforces the possibility that these responses may have been due to direct sensing by the alpha cells of glycopenia rather than concurrent beta-adenergic stimulation from circulating catecholamines. The effects of pancreas transplantation in humans with type I diabetes mellitus on glucose and hormonal counterregulatory responses to hypoglycemia, and on secretion of glucagon, catecholamines, and pancreatic polypeptide in general, have not been previously reported. The only other report addressing glucagon responsivity after hypoglycemia or other stimulation in pancreas recipients is that of Bosi et al. (26) who reported intact glucagon responses to hypoglycemia in five of six patients who received segmental pancreas allografts. However, this study did not include control data from diabetics or normal subjects for comparison, nor did it provide pretransplantation data from their recipients. Hence, one cannot be certain from their report alone whether segmental transplantation improved glucagon responses or counterregulation of hypoglycemia. The only other relevant report is from Ostman et al. (20) who reported only basal but not stimulated glucagon levels.
The importance of these studies at a pragmatic level lies in the widely recognized observation that absence of glucagon responses to hypoglycemia in patients with type I diabetes mellitus is an important consequence which generally begins to become evident several years after diagnosis of the disease. This leads to deranged counterregulation of hypoglycemia and significant clinical risks. In view of the augmented glucagon responses and improved counterregulation of hypoglycemia demonstrated in our study, it may be reasonable to consider pancreas transplantation in type I diabetic patients who are at proven risk for serious episodes of insulin-induced hypoglycemia and who demonstrate refractoriness to conventional medical management with diet, alteration of insulin dosage, and exogenous glucagon injections.
